Newsgather

Ebitda

Steady16 stories5 sourcesLast updated: 4d ago

Latest Stories

Sun Pharma Acquires Organon & Co for $11.8 Billion in Largest-Ever Overseas Pharma Deal by Indian Company
Urgent
Business·4/28/2026AI summary

Sun Pharma Acquires Organon & Co for $11.8 Billion in Largest-Ever Overseas Pharma Deal by Indian Company

Sun Pharma, India's largest pharma company, has acquired US-listed Organon & Co for $11.8 billion (Rs 98,000 crore) in an all-cash transaction — the biggest-ever overseas pharma deal by an Indian company. Sun Pharma will pay $14 per share, a 24% premium to Organon's closing price. The acquisition adds over 140 high-growth markets including China, and portfolio of women's health, biosimilars, and legacy brands. Once completed, it will double Sun Pharma's revenue to $12.4 billion and EBITDA to $3.7 billion, ranking it among top 25 global pharmaceutical companies.

T
Times of India
Stanislao Fabbrino nuovo presidente di Granarolo,替换Gianpiero Calzolari dopo 17 anni
NEWS
4/21/2026AI summary

Stanislao Fabbrino nuovo presidente di Granarolo,替换Gianpiero Calzolari dopo 17 anni

Stanislao Fabbrino è il nuovo presidente di Granarolo, sostituendo Gianpiero Calzolari che ha guidato l'azienda dal 2009. Calzolari, che ha compiuto 70 anni, si è dimesso per favorire il passaggio generazionale dopo 17 anni di leadership. Fabbrino, ingegnere con Mba, è presidente e amministratore delegato di Fruttagel dal 2011 e amministratore delegato di Deco Industrie da maggio 2022.

R
Repubblica Economia
Severstal Q1 2026 Net Profit Plummets 360-Fold to 57 Mln Rubles
NEWS
4/21/2026AI summary

Severstal Q1 2026 Net Profit Plummets 360-Fold to 57 Mln Rubles

Severstal reported a dramatic 360-fold decline in Q1 2026 net profit to 57 million rubles ($0.76 million) from 21.07 billion rubles a year earlier. Revenue fell 19% to 145.3 million rubles, while EBITDA dropped 54% to 17,940 million rubles with margin contracting to 12% from 22%. Free cash flow turned negative at -40.37 million rubles due to EBITDA decline, working capital outflows, and investment program costs.

T
TASS